All In Biotech

Free tool

FAERS Monitor: Zirabev

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761099 or its brand name (Zirabev, Bevacizumab-Bvzr). Reports on generic versions are filed under their own applications.

Reports

705

Serious

568

81% of reports

Hospitalization

166

Death reported

207

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use171
  • death162
  • neoplasm progression82
  • fatigue68
  • weight decreased47
  • hypertension46
  • blood pressure increased44
  • weight increased37
  • inappropriate schedule of product administration32
  • malaise32
  • asthenia30
  • nausea30
  • dyspnoea27
  • blood pressure fluctuation26
  • blood pressure systolic increased26

Reports by year received

View as table
YearReports
202039
202191
2022159
2023164
2024148
202566
202638

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,454 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal8270.557.55,548
blood pressure systolic increasedSignal2639.827.3945
blood pressure fluctuationSignal2632.422.2759
blood pressure increasedSignal448.66.5289
hypertensionSignal466.54.9210
off label useSignal1715.85.1708
deathSignal1625.64.9635
inappropriate schedule of product administrationSignal325.33.8108
weight decreasedSignal475.03.8149
weight increasedSignal374.93.6113
fatigueSignal682.62.168
astheniaSignal302.41.723
malaiseSignal322.21.620
dyspnoea271.41.03
nausea301.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.